Consolidated Statement of Operations - USD ($)	12 Months Ended
Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Sales	$ 1,218,862	$ 714,158
Cost of sales	247,772	172,850
Gross Profit	971,090	541,308
Compensation and related expenses	(532,421)	(558,968)
Professional fees	(114,890)	(139,551)
Marketing expenses	(230,661)	$ (57,248)
Research and development expenses	(23,925)
General and administrative expenses	(331,410)	$ (316,420)
Operating (Loss)	(262,217)	$ (530,879)
Gain on sale of Adiuvo Investment S.A. stock	$ 127,261
License Fee		$ 50,000
Other income		7,877
Interest (expense)	$ (37,476)	(4,683)
Net (Loss) Before Taxes	(172,432)	(477,685)
Deferred income tax benefit	13,200	17,200
Net (Loss)	(159,232)	$ (460,485)
Net (loss) attributable to noncontrolling interests	(97,240)
Net (Loss) attributable to Immudyne, Inc.	$ (61,992)	$ (460,485)
Basic and diluted (loss) per share attributable to Immudyne, Inc.	$ 0.00	$ (0.02)
Weighted average number of common shares outstanding	30,810,000	30,372,000

Represents the expense recognized during the period arising from equity-based compensation arrangements and related expenses (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

No definition available.